Abstract 1159P
Background
The clinical presentation of patients (pts) diagnosed with melanoma of unknown primary (MUP) is not clearly known, like their therapeutic assignment and their evolution in terms of responses obtained, toxicity, and relapse profile in the actuality.
Methods
GEM1801 is a prospective observational study including pts with melanoma that analyzes the clinical and pathological disease presentation patterns, the different lines of treatment choices and the health outcomes derived from treatments. Here we focus on the clinical and evolution characterization of pts diagnosed with MUP.
Results
From Aug 2018 to Dec 2022, 893 evaluable pts were enrolled, 133 (14.9%) being MUP. Median age was 63 years (range 24-93), 81 (60.9%) male. Distal metastases were present in 117 (88%) pts with most (50.4%) having ≥ 3 affected organs, including ganglia (53.4%), lung (41.4%) or brain (30.1%). LDH was elevated in 50 (37.6%) pts. BRAF was mutated in 79 (54.9%) pts. Adjuvant therapy was administered to 28 (21.1%) pts with MUP, being immunotherapy less frequently prescribed than in pts with known primary (17.3% vs 27.1%; p=0.017). Immunotherapy was also less frequent for the 1st line in the metastatic/locally advanced setting (53.6% vs 64%; p=0.039). Conversely, more pts with MUP were enrolled in clinical trials exploring combo of immunotherapy and targeted therapy (9.1% vs 4.8%; p=0.074). Table: 1159P
N, (%) | Median PFS (95% CI), months | Median OS (95% CI), months | |
BRAF + IT | 17 (12.8) | 18.9 (4.4-NR) | 24.9 (24.1-NR) |
BRAF + TT | 40 (30.1) | 13.3 (7.1-27.5) | 13.9 (8.3-NR) |
BRAF - IT | 41 (30.8) | 6.7 (3.5-NR) | 17.9 (9.6-NR) |
IT = Immunotherapy; TT = Targeted therapy.
Conclusions
MUP in Spain comprises a population with a multiorgan presentation and frequent brain metastasis, which was followed by worse outcomes than the general melanoma population. Having MUP diagnosis seems to influence the therapeutic assignment, specially for immunotherapy schemes.
Clinical trial identification
NCT03605771.
Editorial acknowledgement
We acknowledge MFAR Clinical Research staff for their assistance in the development of this abstract.
Legal entity responsible for the study
Grupo Español Multidisciplinar de Melanoma (GEM).
Funding
GEM through industry partners Novartis, Pierre Fabre, Incyte, BMS, Roche y MSD.
Disclosure
E. Muñoz-Couselo: Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, MSD, Novartis, Pierre Fabre, Sanofi, Roche; Other, Personal, Advisory Board: Amgen, BMS, MSD, Novartis, Pierre Fabre, Roche, Sanofi; Other, Personal, Other, Honoraria: Amgen, BMS, Novartis, Pierre Fabre, Roche; Other, Personal, Principal Investigator: Amgen, BMS, GSK, MSD, Novartis, Pierre Fabre, Roche, Sanofi. E. Espinosa: Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, Novartis, Pierre Fabre; Financial Interests, Personal, Advisory Role: MSD. L.A. Fernández-Morales: Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, MSD, Pierre Fabre, Roche, Novartis, Pfizer. T. Puértolas: Financial Interests, Personal, Advisory Role: Bristol Myers Squibb, Immunocore, Novartis, Seagen; Other, Personal, Other, Travel, Accommodation, Expenses: Novartis, MSD, Pierre Fabre. I. Márquez-Rodas: Financial Interests, Personal, Advisory Board: BMS, MSD, Novartis, Pierre Fabre, Roche, GSK, AstraZeneca, Celgene, Regeneron, Sanofi, Merck Serono, Highlight Therapeutics, Bioline Rx, Sun Pharma, Immunocore; Financial Interests, Personal and Institutional, Coordinating PI: Pierre Fabre; Financial Interests, Institutional, Coordinating PI, GEM1802 clinical trial: Novartis; Financial Interests, Institutional, Coordinating PI, GEM1801 clinical study: BMS, Roche, Pierre Fabre, Incyte, MSD; Financial Interests, Institutional, Coordinating PI, National coordinator of Spotlight 203 clinical trial: Highlight Therapeutics; Non-Financial Interests, Advisory Board: Spanish Melanoma group. All other authors have declared no conflicts of interest.
Resources from the same session
1139P - Final results of a phase II study of pembrolizumab as first-line treatment in advanced cutaneous squamous cell carcinomas (CSCCs)
Presenter: Eve Maubec
Session: Poster session 13
1140P - Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA
Presenter: Emilie Gerard
Session: Poster session 13
1141P - Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma
Presenter: Elena Croce
Session: Poster session 13
1142P - Personalized decision making in cutaneous squamous cell carcinoma: Integrating a clinico-pathological model for absolute metastatic risk into the staging systems
Presenter: Marlies Wakkee
Session: Poster session 13
1143P - Changes in peripheral and local tumor immunity after cemiplimab treatment early describe clinical outcomes in patients with cutaneous squamous cell carcinoma
Presenter: Daniela Esposito
Session: Poster session 13
1144P - High-plex spatial profiling of cutaneous squamous cell carcinoma to identify biomarkers associated with clinical outcomes: The cMIC study
Presenter: Rahul Ladwa
Session: Poster session 13
1145P - Clinical characteristics and survival of patients with advanced Merkel cell carcinoma (MCC) treated with avelumab: Analysis of a prospective German MCC registry (MCC TRIM)
Presenter: Juergen Becker
Session: Poster session 13
1146P - Updated results from POD1UM-201: A phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC)
Presenter: Giovanni Grignani
Session: Poster session 13
1148P - Avelumab as second-line or later (2L+) treatment (tx) in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Real-world tx patterns in France
Presenter: Astrid Blom Fily
Session: Poster session 13